Skip to main content


  • Monday, Aug 25th
    9:30 AM - 9:45 AM ET
    3B-06 - Timing of antidiabetic medication initiation and risk of major adverse cardiovascular events and mortality: A target trial emulation with clone-censor-weight approach
    Presenting Author: Hwa Yeon Ko, PharmD – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
    Co-Author: Yunha Noh – College of Pharmacy, Chonnam National University, Gwangju, South Korea.
    Co-Author: Bin Hong – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
    Co-Author: Kyungyeon Jung, PharmD – Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea
    Co-Author: Ju-Young Shin, PharmD, PhD – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
    Safety Outcomes / Diabetes
  • Tuesday, Aug 26th
    8:30 AM - 8:45 AM ET
    5E-01 - Safety and effectiveness of GLP-1 receptor agonists among insulin-treated persons with type 1 diabetes
    Presenting Author: Yunwen Xu – Johns Hopkins University
    Co-Author: Michael Fang – Johns Hopkins University
    Co-Author: Alexander Chang – Geisinger Health
    Co-Author: Justin Echouffo Tcheugui – Johns Hopkins University
    Co-Author: Elizabeth Selvin – Johns Hopkins University
    Co-Author: Morgan Grams – New York University
    Co-Author: Jung-Im Shin – Johns Hopkins University
    Safety Outcomes / Diabetes
  • Tuesday, Aug 26th
    8:45 AM - 9:00 AM ET
    5E-02 - Risk of Diabetes in People Living with HIV Associated with Remaining on a TDF-containing Antiretroviral Regimen or Switching to a TAF-containing Regimen or Another Regimen Without Tenofovir
    Presenting Author: Randall L. Kuffel, ScM – Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
    Co-Author: Lianeris M. Estremera-Rodriguez, MS, JD – Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
    Co-Author: Y. Joseph Hwang, MD, MSc – Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America
    Co-Author: Jason Haw – Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
    Co-Author: Jeanne Keruly – Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America
    Co-Author: Lauren Zalla – Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
    Co-Author: LaQuita Snow – Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America
    Co-Author: Joyce Jones, MD, MS – Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America
    Co-Author: Richard D. Moore, MD – Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America
    Co-Author: Anthony Fojo – Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America
    Co-Author: Catherine Lesko, PhD, MPH – Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
    Safety Outcomes / Diabetes
  • Tuesday, Aug 26th
    9:45 AM - 10:00 AM ET
    5E-06 - Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in patients with Type 2 Diabetes
    Presenting Author: Salvatore Crisafulli – University of Verona
    Co-Author: Wajd Alkabbani, PhD – Brigham and Women's Hospital
    Co-Author: Julie M. Paik, MD, ScD – Brigham and Women's Hospital
    Co-Author: Katsiaryna Bykov, PharmD, ScD – Brigham and Women's Hospital
    Co-Author: Ali Tavakkoli – Brigham and Women's Hospital
    Co-Author: Robert Glynn – Brigham and Women's Hospital
    Co-Author: Elaine Yu – Massachusetts General Hospital
    Co-Author: Gianluca Trifirò – Department of Diagnostics and Public Health, University of Verona, Verona, Italy
    Co-Author: Deborah J. Wexler, MD, MSc – Massachusetts General Hospital
    Co-Author: Elisabetta Patorno, MD, DrPH – Brigham and Women's Hospital
    Safety Outcomes / Diabetes
  • Tuesday, Aug 26th
    2:15 PM - 2:30 PM ET
    6A-04 - Evaluating the real-world effect of CYP2C9-inhibiting selective serotonin reuptake inhibitors on the incidence of serious hypoglycemia among Medicare-insured sulfonylurea users
    Presenting Author: Sara Z. Dejene, MSPH – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
    Co-Author: Virginia Pate – University of North Carolina at chapel hill
    Co-Author: Til Stürmer, MD, PhD – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
    Co-Author: John Buse, MD, PhD – School of Medicine, University of North Carolina at Chapel Hill
    Co-Author: Craig R. Lee, PharmD, PhD – Division of Endocrinology and Metabolism, School of Medicine, University of North Carolina at Chapel Hill
    Co-Author: Charles Poole, ScD – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
    Co-Author: Michele Jonsson Funk, PhD – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
    Safety Outcomes / Diabetes
  • Tuesday, Aug 26th
    2:30 PM - 2:45 PM ET
    6G-05 - Timing of SGLT2 inhibitors Initiation on Clinical Complications in Diabetic Metabolic Dysfunction-Associated Steatotic Liver Disease: A Target Trial Emulation Study With a Clone-Censor-Weight Approach
    Presenting Author: Kyungyeon Jung, PharmD – Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea
    Co-Author: Hwa Yeon Ko, PharmD – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
    Co-Author: Bin Hong – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
    Co-Author: Ju-Young Shin, PharmD, PhD – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
    Safety Outcomes / Diabetes